NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.345) was uploaded to the NHS England Website on Tuesday 4, February 2025.
The following changes have been introduced:
Avapritinib monotherapy (AVA1)
For the treatment of aggressive systemic mastocytosis or aggressive systemic mastocytosis with an associated haematological neoplasm or mast cell leukaemia where the following criteria have been met
Moved into routine commissioning - section B of list
Olaparib (OLAP10)
Olaparib as monotherapy for treatment of adults with deleterious or suspected deleterious germline BRCA1 or 2 mutations who have HER-2 negative locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane in the adjuvant/neoadjuvant/advanced disease settings and also treated with prior endocrine-based therapy if the patient has hormone-receptor positive disease where the following criteria have been met
Treatment criterion (#8) updated
Talazoparib monotherapy (TAL1)
Talazoparib as monotherapy for treatment of adults with deleterious or suspected deleterious germline BRCA1 or 2 mutations who have HER-2 negative locally advanced or metastatic breast cancer previously treated with an anthracycline and/or taxane in the adjuvant/neoadjuvant/advanced disease settings and also treated with prior endocrine-based therapy if the patient has hormone-receptor positive disease where the following criteria have been met
Treatment criterion (#8) updated
Tivozanib (TIV1)
The treatment of advanced renal cell carcinoma where all the following criteria are met:
Treatment criterion (#4) updated